Lv44
424 积分 2025-09-03 加入
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
8小时前
已完结
The current state of the art and future trends in RAS-targeted cancer therapies
13天前
已完结
Combinatorial strategies to target RAS-driven cancers
18天前
已完结
Combinatorial strategies to target RAS-driven cancers
18天前
已完结
A binding-to-release strategy for targeted anticancer drug delivery
1个月前
已完结
Datopotamab Deruxtecan: First Approval
1个月前
已完结
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
1个月前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
1个月前
已完结
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
2个月前
已完结
A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma
2个月前
已完结
皖公网安备34019202002308
